216 results found.
Top 10 Takeaways from Orthopedics in 2019
Enabling Technology and Integrated Selling Strategies Drove Orthopedic Growth in the Third Quarter
The third quarter of 2019 brought some standout performances from large players like Stryker, Medtronic, NuVasive and Globus Medical. DePuy Synthes and Zimmer Biomet made incremental progress in returning to market growth. Notably, the top performing players all have well-established enabling tec...
Integra LifeSciences Sees Modest Orthopedic Growth from Dedicated Sales Channel
Integra LifeSciences reports 3Q19 orthopedic revenue of USD $20.9MM, +1.6% vs. 3Q18.
Orthopedic Public Companies Grow 2.6% YoY in Quarter
By Mike Evers The second quarter of 2019 brought incremental improvement over the first. Year over year revenue grew 2.6% in the quarter for the public companies reported herein compared to 1.1% last quarter. The five largest orthopedic players, which control 58% of the market, showed a...
Integra LifeSciences Reports 2Q19 Orthopedic Revenue of $21.8MM, -1.2% vs. 2Q18
Integra LifeSciences reports 2Q19 orthopedic revenue of USD $21.8MM, -1.2% vs. 2Q18.
FDA 510(k) Recap: Spinal Devices and Technologies from 1H19
By Julie A. Vetalice With the NASS 2019 Annual Meeting approaching, I thought it an ideal time to revisit spine products that have gained FDA 510(k) clearance in the first half of the year. (I’ve included booth numbers for companies that have already reserved their space at the ev...
Orthopedic Sales in Line with Seasonal Expectations for 1Q19
By Mike Evers The first quarter of 2019 brought modest growth to the orthopedic market, as expected seasonal softness and more competition in digital surgery platforms slowed sales for some of the largest players. The 25 companies listed herein had combined total orthopedic sales of $8....
Integra LifeSciences Reports 1Q19 Orthopedic Revenue of $22.7MM, +0.2% vs. 1Q18
Integra LifeSciences reports 1Q19 orthopedic revenue of USD $22.7MM, +0.2% vs. 1Q18.
Orthopedic Industry Revenue Reaches $51 Billion in 2018
By Mike Evers Download Your Copies
Revenue Review: 4Q18 and Full Year 2018 Performance Highlights for Public Companies
By Mike Evers Below you’ll find a summary of the major 4Q18 and full year 2018 developments for publicly-traded orthopedic companies. Exhibits 1 and 2 show 4Q18 and full year performance, respectively.  Companies continue to refine their strategies to improve sales mix ...
Integra LifeSciences Reports 4Q18 Orthopedic Revenue of $25.4MM, -8.1% vs. 4Q17
Integra LifeSciences reports 4Q18 orthopedic revenue of USD $25.4MM, -8.1% vs. 4Q17, with
Integra LifeSciences Launches Panta 2 TTC Arthrodesis Nail
Integra LifeSciences introduced the Panta® 2 TTC Arthrodesis Nail for tibio-talo-calcaneal fusion. 
Integra LifeSciences Launches Titan Reverse Shoulder System-S
Integra LifeSciences commenced full market launch of the Integra® Titan™ Reverse Shoulder System-S, featurin...
Integra Enters Agreement to Develop a Short Stem and Stemless Shoulder System
Integra LifeSciences entered into a license and development agreement with Consortium of Focused Orthopedists for a s...
Revenue Review: 3Q18 Performance Highlights and 2018 Projections for Public Companies, Continued
By Mike Evers In the exhibits below, we've added nine companies to round out our revenue review for 3Q18. As noted in last month's 
First Procedures with Integra's XT Revision Total Ankle
Integra LifeSciences launched the Integra® XT Revision Total Ankle Replacement system.
3Q18 and 9 Month 2018 Performance Highlights for Public Companies
By Mike Evers Our recap highlights 3Q18 developments and ORTHOWORLD's projection of 2018 full-year revenue for the first publicly traded orthopaedic companies to report. Exhibits 1 and 2 below show year over year company performance for 3Q18 and nine months ending September 30, 2018...
SeaSpine Reports 3Q18 Revenue of $35.8MM, +12.9% vs. 3Q17
SeaSpine picks up momentum, posts 3Q18 revenue of US $35.8MM, +12.9% vs. 3Q17.
Integra LifeSciences Reports 3Q18 Revenue
Integra LifeSciences reports 3Q18 results; ORTHOWORLD estimates orthopaedic revenue of $22.7M, -0.8% vs. 3Q17.
SeaSpine Prices $50MM Public Offering of Stock
SeaSpine closed its underwritten public offering of 3,250,000 shares of its common stock for US $15.50/share, for gross proceeds of ~$50.4MM.
Joint Reconstruction Expected to Continue with Steady Growth
By Carolyn LaWell Joint reconstruction accounts for 37% of the global orthopaedic industry. We estimate that joint reconstruction product revenue surpassed $18 billion in 2017, an increase of $560.3 million or 3.2% vs. 2016. These numbers were published in
SeaSpine 2Q18 Revenue +7% vs. 2Q17
SeaSpine announced 2Q18 revenue of US $36.4MM, +6.5% vs. 2Q17, and 1H18 revenue of $69.6MM, +5.3% vs. 1H17. Thi...
Integra LifeSciences Reports 2Q18 Revenue
ORTHOWORLD estimates Integra LifeSciences’ 2Q18 orthopaedic revenue at US $30.4MM, -0.6% vs. 2Q17, and 1H18 revenue of $5...
Integra LifeSciences Reports 1Q18 Orthopaedic Revenue
ORTHOWORLD estimates Integra LifeSciences’ 1Q18 orthopaedic revenue at US $24.8M, -4.8% from 1Q17.
Integra LifeSciences Posts 4Q17, 2017 Revenue
ORTHOWORLD estimates Integra LifeSciences’ 4Q17 orthopaedic revenue at US $27.42MM, +7.3% from 4Q16, and 2017
  • 8401 Chagrin Road, Suite 18
  • Chagrin Falls, Ohio 44023 USA
  • Phone: 440.543.2101 • Fax: 440.543.2122
  • ©1992-2020 ORTHOWORLD
  • All Rights Reserved.
  • Site Managed By:
  • Open Professional Group